Suspensions of pro-drug insulin greatly prolong normoglycemic patterns in diabetic rats

Biochemical and Biophysical Research Communications

Volumn 307, Issue 2, 2003, Pages 315-321

  Shechter, Yoram ^a   Tsubery, Haim ^a   Fridkin, M ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Diabetes; FMS3 insulin; Glucose lowering profiles; Long acting insulin; Normoglycemia; Prodrug insulin

Indexed keywords

(2 SULFO 9 FLUORENYLMETHOXYCARBONYL) 3 INSULIN; ANTIDIABETIC AGENT; INSULIN DERIVATIVE; ISOPHANE INSULIN; PRODRUG; PROTAMINE; UNCLASSIFIED DRUG; ZINC ION;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOSYNTHESIS; CRYSTALLIZATION; DRUG SYNTHESIS; GLUCOSE BLOOD LEVEL; NONHUMAN; PRIORITY JOURNAL; RAT; STREPTOZOCIN DIABETES;

EID: 0038690338     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-291X(03)01200-2     Document Type: Article

References (31)

1. Home P.D. Insulin therapy. Albert K.G.M.M., Zimmet P., Defronzo R.A. The International Textbook of Diabetes. second ed. 1996;899-928 Wiley, Chichester, UK.
2. Hallas-Moller K., Peterson K., Schlichtrull J. Crystaline and amorphous insulin-zinc compounds with prolonged action. Science. 116:1952;394-399.
3. Shechter Y. Evaluation of adenosine and related nucleosides as physiological regulators in adipose tissue. Endocrinology. 110:1982;1579-1583.
4. Shechter Y., Reitman P., Hizi A. Evaluation of factors responsible for the inability of insulin to antagonize lipolysis due to high concentrations of catecholamines. Biochem. Biophys. Res. Commun. 109:1982;776-785.
5. Porte D. Jr., Halter J.B. The endocrine pancreas and diabetes mellitus. Williams R.H. Textbook of Endocrinology. sixth ed. 1981;716-743 W.B. Saunders, Philadelphia.
6. Kahn C.R., Shehcter Y. Insulin, oral hypoglycemic agents and the pharmacology of the endocrine pancreas. Gilman A.G., Rall T.W., Nies A.S., Taylor P. Goodman and Gilman Handbook of Pharmacology. 1990;1463-1495 Pergamon Press, New York/Oxford.
7. Foster D.W. From glycogen to ketones and back. Diabetes. 33:1984;1188-1199.
8. Davis S.N., Granner D.K. Insulin, oral hypoglycemic agents and the pharmacology of the endocrine pancreas. Handman J.G., Limbial L.E., Molinoff P.B., Ruddon R.W. Goodman and Gilman. The Pharmacological Basis of Therapeutics. ninth ed. 1996;1487-1517 Pergamon Press, New York.
9. Hildebrant P. Subcutaneous absorption of insulin in insulin-dependent diabetic patients. Dan. Med. Bull. 38:1991;337-346.
10. Hoffman A., Ziv E. Pharmacokinetic considerations of new insulin formulations and routes of administration. Clin. Pharmacokinet. 33:1997;285-301.
11. Bolli G.B., DiMarchi R.D., Park G.D., Pramming S., Koivisto V.A. Insulin analogues and their potential in the management of diabetes mellitus. Diabetologia. 42:1999;1151-1167.
12. Galloway J.A., Chance R.E. Improving insulin therapy: achievements and challenges. Horm. Metab. Res. 26:1994;591-608.
13. Albert K.G.M.M. Insulin treatment and diabetes; half a century of therapeutic misadventure? Tanbridge W.M.G. Advanced Medicine. 1981;1-13 Pitman, Bath, UK.
14. Scott D.H., Fisher A.M. Insulin and protamine. J. Pharmacol. 58:1936;78-92.
15. Thow J.C., Johnston A.B. Effect of raising injection site temperature on isophane insulin crystal dissociation. Diabetes Care. 12:1989;432-434.
16. Lauritzen T., Pramming S., Gale E., Deckert T., Binder C. Absorption of isophane (NPH) insulin and its clinical implications. Br. Med. J. 285:1982;159-162.
17. Bolt S., Bolt U., Berger M., Mulhauser I. Intensified insulin therapy and the risk of severe hypolycaemia. Diabetologia. 40:1997;926-932.
18. Muhlhauser I., Overmann H., Bender R., Bolt V., Berger M. Risk factors of severe hypoglycaemia in adult patients with Type I diabetes - a prospective population based study. Diabetologia. 41:1998;1274-1282.
19. Gershonov E., Shechter Y., Fridkin M. New concept for long-acting insulin. Spontaneous conversion of inactive modified insulin to the active hormone in circulation; 9-fluorenylmethoxycarbonyl derivative of insulin. Diabetes. 48:1999;1437-1442.
20. 3-insulin. J. Med. Chem. 43:2000;2530-2537.
21. 2. Proc. Natl. Acad. Sci. USA. 98:2001;1212-1217.
22. Shechter Y., Goldwaser I., Lavon I.et al. A new concept for prolonging the half-life of peptides, proteins, and low molecular weight drugs in vivo. Drug. Future. 26:2001;669-676.
23. Duckworth W.C. Insulin-degradation: mechanism, products, and significance. Endocr. Rev. 9:1988;319-345.
24. Merrifield R.B., Bach A.E. 9-(2-Sulfo)fluorenylmethoxy carbonyl chloride, a new reagent for the purification of synthetic peptides. J. Org. Chem. 43:1978;4808-4816.
25. Meyerovitch J., Farfel Z., Sack Y., Shechter Y. Oral administration of vanadate normalizes blood glucose levels in streptozotocin-treated rats. J. Biol. Chem. 262:1987;6658-6662.
26. Blundell T., Dodson G., Hodgkin D., Mercola D. Insulin: the structure in the crystal and its reflection in chemistry and biology. Adv. Protein Chem. 26:1972;279-402.
27. Baker E.N., Blundell T.L., Cutfield S.M.et al. The structure of 2Zn pig insulin crystals at 1.5. Å resolution Philos. Trans. R. Soc. Lond. 319:1988;369-456.
28. Fisher A.M., Scott D.A. The effect of various substances on the action of insulin. J. Pharmacol. 58:1936;93-104.
29. Kobayashi M., Olefsky J.M. Effect of streptozotocin-diabetes on insulin binding, glucose transport, and intracellular glucose metabolism in isolated rat adipocytes. Diabetes. 28:1979;95-97.
30. Goldwaser I., Li J., Gershonov E., Armoni M., Karnieli E., Fridkin M., Shechter Y. L-Glutamic acid (. γ) -monohydroxamate; a potentiator of vanadium-evoked glucose metabolism in vitro and in vivo J. Biol. Chem. 274:1999;26617-26624.
31. Shechter Y. Perspective in diabetes; insulin-mimetic effects of vanadate: possible implications for future treatment of diabetes. Diabetes. 39:1990;1-5.